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ISStaphylococcus aureus is a Gram-positive facultative aerobic, nonmotile coccus that is
an opportunistic pathogen in both humans and animals. A new window was opened for
eradication of infections by bacteria with the discovery of antibiotics. Plasmid-borne
resistance genes appeared soon afterwards. Currently, the distribution of antibiotic-
resistant genes between bacteria via horizontal and vertical transformation and pre-
scription of antibiotics has severely complicated treatment of infection. Antibiotic
resistant bacteria have become a worldwide concern. Methicillin-resistant Staphylo-
coccus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus are now
recognized as problematic bacteria. The current review aims to cover some aspects
of MRSA and its distribution worldwide.
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vancomycin-resistant Staphylococcus aureusIntroduction
Staphylococcus aureus is a Gram-positive coccus, facultative
aerobic, and grows as grape-like clusters; it is an oppor-
tunistic pathogen for both humans and animals. The most
common infections by S. aureus are skin and soft tissue
infections, respiratory infections and food poisoning [1].Carriage of Staphylococcus aureus
Naturally, S. aureus colonizes humans and can be found in
the throat, perineum, groin, anterior nares and skin.
Nasal carriage of S. aureus is one of the common risk
factors causing infections in the community and in
hospitals [2,3]. Nasal carriage of S. aureus is associated
with infection in patients with underlying diseases
including AIDS, insulin-dependent diabetes mellitus,
continuous ambulatory peritoneal dialysis and skin
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SN 0954-139X Q 2014 Wolters Kluwer HPrevalence of S. aureus nasal carriage varies from 9 to
100%, with a mean of 37% [6]. S. aureus nasal carriage
rates varied with the age of the human individual [3,6];
there is higher rate of S. aureus nasal carriage among
children than among adults. It is more prevalent between
the ages of 10 and 20 years [7]. In addition, the rate of S.
aureus nasal carriage was found to be higher in boys than
in girls and is therefore associated with the hormonal
status [8]. Different strains of S. aureus can be found in the
colonized individual potentially stimulating the horizon-
tal transfer of antimicrobial-resistant genes [9].Staphylococcus aureus infections
S. aureus causes many diseases in humans, including skin
and soft tissue infections (abscesses, carbuncles, folliculitis,
furuncles, impetigo, bullous impetigo and cellulitis),
which in the absence of antimicrobial therapy may lead toal Sciences, Ilam, Iran, and the bDepartment of Medical
ciences, University Putra Malaysia, Selangor, Malaysia.
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infections caused by S. aureus include endocarditis,
pneumonia, bone and joint infections. S. aureus skin
infections are frequent in the United States, Canada, Latin
America, Europe and the Western Pacific, although it is
isolated from cases of pneumonia and bloodstream
infection worldwide [11]. Wound and catheter-related
infections are closely associated with S. aureus. One
primary cause of nosocomial bacteraemia is associated
with intravascular catheter-related infections [12]. Toxin-
mediated diseases such as toxic shock syndrome and food
poisoning are associated with TSST-1 and enterotoxin-
producing S. aureus [13].Methicillin-resistant Staphylococcus
aureus
History of methicillin-resistant Staphylococcus
aureus
The 1940s saw the introduction of penicillin, the first
antimicrobial agent effective against S. aureus. Sub-
sequently, resistance to penicillin was observed [14] and a
plasmid harbouring b-lactamase gene was found to be
responsible for creation of penicillin-resistant S. aureus
[15]. Penicillin-resistant S. aureus became a worldwide
concern during the next two decades. In 1959,
methicillin (a semi-synthetic derivative of penicillin
and resistant to the b-lactamase enzyme) was used for
treatment of infections caused by penicillin-resistant S.
aureus. After that, penicillin-resistant S. aureus decreased
significantly [16]. The first isolates of methicillin-resistant
S. aureus (MRSA) were reported in 1961 [17]. Until the
late 1970s, the prevalence of MRSA was considered
sporadic, but MRSA was soon observed worldwide [18].M
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Fig. 1. Peptidoglycan structure of Staphylococcus aureus.MRSA is now a major cause of morbidity and mortality
[19], and increasingly prevalent in many regions [20].
Mechanism of resistance to methicillin in
Staphylococcus aureus
Penicillin-binding proteins: the targets of b-lactam
antibiotics
Peptidoglycan structure in Staphylococcus aur-
eus The S. aureus cell wall comprises a very thick layer
of peptidoglycan. The structure of the cell wall is a repeat
of b1–4-linked N-acetylglucosamine-N-acetylmuramic
acid (NAM) with attached teichoic acids [21]. Each NAM
is cross-linked to four of five amino acid chains containing
L-alanine, D-iso-glutamine, L-lysine andD-alaninewith a
penta-glycine bridge between L-Lysine and D-alanine
(Fig. 1).
The bridge is formed in the cytoplasm by FemX, FemA
and FemB proteins that bind the glycine residues to the
L-lysine residue of the stem peptides. The cross-linking
occurs on the external layer of the cytoplasmic membrane
in a reaction catalyzed by penicillin-binding proteins
(PBPs). The PBPs are divided into four types, namely
PBP1, PBP2, PBP3 and PBP4.
The PBPs have two protein domains, one of the domains
is in cross-linking and another in transglycosylation.
b-lactam antibiotics such as methicillin and oxacillin bind
to the terminal D-alanyl-D-alanine of the stem peptide,
thereby inhibiting the first domain of PBPs (transpepti-
dation) and the initiation of cross-linking. Therefore, the
peptidoglycan is unable to crosslink, allowing leakage of
cytoplasm outside the cell, resulting in the death of the
bacterial cells [22]. MRSA has developed a different
foreign PBP called PBP2a (resistant to methicillin). 
G
M
M
M
M
M
M
M
M
G
G
G
G
G
G
G
G
G
CE: Swati; R695; Total nos of Pages: 7;
R695
Methicillin-resistant Staphylococcus aureus Ghafourian et al. 3Penicillin-binding protein 2a
The difference between methicillin-sensitive S. aureus
andMRSA is the presence ofmecA gene, which encodes a
different 78-kDa PBP (PBP2a). The mecA gene is
originally from Staphylococcus sciuri [23]. CcrA and B,
located in mec element, code a recombinase protein that is
responsible for unifying and fission of the mec element
into the chromosome [24]. The mec element is highly
conserved between different isolates. PBP2a is a motif
from the other PBP, which has a low affinity to bind with
b-lactam antibiotics. Notably, resistance to methicillin
and other b-lactam antibiotics in S. aureus is associated
with mobile staphylococcal chromosomal cassettes that
harbour the mecA gene and is known as Staphylococcal
chromosomal cassettes mecA (SCCmecA) [24].
The ccr gene complex
The ccr gene complex includes the ccr genes and ORFs. S.
aureus has three different ccr genes, which are ccrA, B and
C. CcrA and B are divided into four different allotypes.
Ccr genes, which have more than 85% similarity in their
sequences, are classified as the same allotype. The ccrC
gene has more than one different allele, ccrC1 allele 2,
ccrC1 allele 3. Different ccr have different allotypes; for
example, S. aureus type 1 harboured ccrA1B1 and type 2
possesses ccrA2B2 [25].
mecA
As mentioned, mecA is associated with resistance to the
b-lactam antibiotics. mecA encodes PBP2a, which is
different from the other PBPs [26]. MecI and mecR1 are
the regulator genes that controlmecA.MecI is the repressor
for mecA, while mecR1 plays a different role as a signal for
transduction cascade [27]. In addition, mecA is also under
control of two corepressors (blaI and blaR1). BlaI is
homologous of mecI and blaR1 is similar to mecR1. These
two corepressors are responsible for controlling blaZ that
is responsible for penicillin resistance [26]. Also, blaI is
able to bind to mecA operator and suppress the
transcription of mecA [28].
Staphylococcal cassette chromosome mec
Staphylococcal cassette chromosome mec (SCCmec) is
known as a genomic island of unknown origin, as it has
the antimicrobial resistance gene mecA [26]. SCCmec also
has other genes including ccrA and ccrB, which code the
recombinase proteins for incorporation and fission of the
SCCmec elements from S. aureus chromosome [26].
SCCmec elements are divided into different types with
various mec and ccr genes. These different SCCmec
elements cause variation of antimicrobial resistance and
different kinds of infections [29]. Types I–III SCCmec are
large elements, which possess other antimicrobial
resistance genes and are found in community-associated
MRSA and hospital-associated MRSA (CDC, 2007). On
the contrary, types IV and V are found more in
community-associated MRSA [29].In all types, the integration occurs in the attBscc site near
to the origin of the replication of S. aureus [30]. There are
three classes ofmec as follows: class Amec contains twomecI
(transcriptional repressor protein) and mecR1 (signal
transduction protein) genes [31], while class B mec
includes mecA (with deletion of mecI and some parts of
mecR1) and insertion sequence 1272 that are incorp-
orated into the deletion site of mecA. Class C2 contains
two copies of insertion sequence 431, mecA (short
mecR1) [32]. Thus, type I SCCmec harbours class B mec
and ccrA; type II SCCmec has class A mec and ccrB; type III
SCCmec contains class Amec and type ccrC; type IV carries
class B mec and type ccrB; and type V possess class C mec
and type 5 ccr. Therefore, naming of a new SCCmec type is
based on ccr complex and class of mec gene.
Public health importance
MRSA is one of the most important antibiotic-resistant
pathogens. There is an increasing prevalence of MRSA
worldwide. ICUs in the United States showed an increase
in MRSA from 36% in 1992 to 64.5% in 2003 [33]. In
Europe, the prevalence ranges from 1 to 50%. The
morbidity and mortality caused by MRSA infections in
the UK increased during the period 1993–2005
(National Statistics, 2007). In 2012, a meta-analysis study
in Iran showed that the prevalence of MRSA ranged from
20.4% in Isfahan to 90% in Tehran. Infections by MRSA
lead to longer term hospitalization and higher care costs
[34].
Surveillance programmes appear to be necessary, such
as the European Antibiotic Resistance Surveillance
System (EARSS), which monitors the seven most
invasive bacteria responsible for antimicrobial resistance
(www.earss.rivm.nl). Currently, one of the most crucial
issues is the presence of MRSA in the community. In
1993, Australia reported the prevalence of the first MRSA
in the community [35]. This was followed by reports of
four MRSA in the community, causing paediatric deaths.
Now, the prevalence of MRSA in the community is
reported worldwide [36], representing a change in the
epidemiology of community-associated and hospital-
associated MRSA worldwide.
Epidemiology
It is estimated that the range of distribution of MRSA is
between 23 and 73%worldwide. MRSA is found to be an
important cause of skin and respiratory infections [11].
Malaysia showed a high prevalence of MRSA in 1996
[37]; MRSAwere found in the surgical wards and linked
to the use of invasive procedures [38].
Europe
It is estimated that the prevalence of MRSA in Europe is
around 26% currently. In the SENTRY programme
between 1997 and 1999, European countries showed
variance in the frequency of prevalence of MRSA
(Fig. 2). These surveys revealed greater prevalence in
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Fig. 2. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in different European countries as SENTRY centres,
1997–1999 [11].southern Europe [11]. Tiemersma et al. [39] revealed the
prevalence of MRSA during the period 1999–2002 in
Belgium, Germany, Ireland, Netherlands and the UK.
The prevalence of MRSA was varied from 1% in
northern Europe to 40% in southern Europe.
Africa
In 1978, the first MRSA was reported in Africa.
Thereafter, the occurrence has ranged from 5 to 45%
[11,37]. The first isolation of MRSA in Sudan was
reported in 1999 [40]. Figure 3 shows the prevalence of
MRSA in different African countries.Tunisia 8.1%
Algeria 45%
Morocco 14.4%
Ivory Coast 16.8%
Nigeria 29.6%
Cameroon 21.3%
Moro co 1 .4%
Algeria 45%
Senegal 12.5%
Nigeria 29.6%
Cameroon 21.3%
r  Coast 16.8%
Tunisia 8.1%
Fig. 3. Prevalence of methicillin-resistant Staphylococcus aureusAsia
The prevalence of MRSA in the Asia Pacific region is
greater than in other parts of Asia with a frequency of
more than 60%. In Malaysia, the prevalence of MRSA
was 17% in 1986 increasing to 40% in 2000 [11]. Figure 4
shows the prevalence of MRSA in the Pacific region.
The United States
In 1974, it was 2%, in 1995, it was 22% and in 2004, it was
reported to be 64%. According to the CDC report, 1.5%
of the populations of the USA were carriers of MRSA
between 2003 and 2004. There was a 50–70% increase inUganda31.5%
Sudan
Kenya 27.7%
Tanzania 16%
Botswana 22.6%
Madagascar~5%
South Africa ~40%
tswana 2.6%
Madagascar~5%
South fri  ~40%
n
Uganda .5%
enya 2 .7%
zania 16%
in different countries in Africa [11].
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China 27.8%
Hong Kong 73.8%
Singapore 62.3%
Malaysia 40% 
Japan71.6% 
Taiwan
61.1%
Philippines
5%
Fig. 4. Prevalence of methicillin-resistant Staphylococcus aureus in different countries in the Asia Pacific region [11].MRSA during the period 2001–2007 in bloodstream
infections [41].
Australia
The first report of MRSA in Australia was observed in the
1960s. The first gentamicin-resistant MRSAwas found in45
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Fig. 5. Prevalence of multiresistant methicillin-resistant Staphylo
resistant Staphylococcus aureus in different cities (nmMRSA) in A1976. Figure 5 shows the prevalence of multiresistant
MRSA and nonmultiresistant MRSA in different parts
of Australia.
Latest evidence worldwide shows that the highest rate of
prevalence (>50%) is in North and South America andnmMRSA
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coccus aureus (mMRSA) and nonmultiresistant methicillin-
ustralia. MRSA, methicillin-resistant Staphylococcus aureus.
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South 
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Fig. 6. Worldwide prevalence of methicillin-resistant Staphylococcus aureus [42–44]. HK, Hong Kong.Asia. Intermediate rates (25–50%) are observed in China,
Australia, Africa and some European countries, including
Portugal (49%), Greece (40%), Italy (37%) and Romania
(34%). The lowest prevalence was reported in the
Netherlands and Scandinavia [42–44]. Very high
prevalence of MRSA was reported from Sri Lanka
(86.5%), South Korea (77.6%), Vietnam (74.1%), Taiwan
(65.0%), Thailand (57.0%) and Hong Kong (56.8%). A
lower frequency is found in India (22.6%) [44]. Figure 6
displays the worldwide prevalence of MRSA.
Risk factors
At-risk populations for MRSA include those with HIV,
lupus erythematosus, cancer, diabetes and those under-
going transplantation [45]. MRSA is a serious risk to
hospitalized patients [46]. People in contact with livestock
animals are also at risk for MRSA infections. In 2011,
24.4% of meat and poultry sold in the United States was
contaminated with MRSA [47]. Athletes are another
group at risk for MRSA associated particularly with
fitness centres in the United States.
Treatment
MRSA are resistant to b-lactam antibiotics. The
resistance to antibiotics in community-acquired MRSA
(CA-MRSA) and hospital-acquired MRSA (HA-
MRSA) is different. CA-MRSA are more susceptible
to cotrimoxazole, tetracycline and clindamycin, but the
choice for treatment of CA-MRSA is vancomycin. HA-
MRSA are susceptible to vancomycin [48] as well as some
newer antibiotics such as linezolid and daptomycin; both
were found to be effective against HA-MRSA and CA-
MRSA. Currently, teicoplanin, vancomycin antibiotics
are the preferred choices for treatment of MRSA.Unfortunately, new strains of MRSA have appeared
that are resistant to vancomycin, known as vancomycin-
resistant S. aureus [49]. Linezolid, daptomycin and
tigecycline are used for treatment of infections by
vancomycin-resistant S. aureus [50].Acknowledgements
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